Core Insights - Vext Science, Inc. reported financial results for Q3 2025, correcting previous inaccuracies in EBITDA and Adjusted EBITDA figures [2][3] - The company achieved a revenue of $12.7 million, representing a 41% year-over-year increase, driven by expanded operations in Ohio and stable performance in Arizona [4][7] - Year-to-date operating cash flow reached $8.5 million, a significant improvement compared to $(0.7) million in the same period last year [7] Financial Performance - Corrected Q3 2025 financial results include: - Revenue: $12,670,000 - EBITDA: $1,828,000 - Adjusted EBITDA: $1,625,000 - Adjusted EBITDA Margin: 12.8% [5][14] - Comparison with previous quarters: - Q2 2025 Revenue: $13,407,000; EBITDA: $5,263,000; Adjusted EBITDA: $4,077,000; Adjusted EBITDA Margin: 30% [5][14] - Q3 2024 Revenue: $8,987,000; EBITDA: $1,925,000; Adjusted EBITDA: $2,873,000; Adjusted EBITDA Margin: 32% [5][14] Operational Highlights - The company expanded its retail footprint in Ohio to five locations, with plans to reach a total of eight dispensaries by 2026 [6][7] - Vext's operations in Arizona continued to outperform state averages on a per-store basis, maintaining steady performance despite market challenges [6][7] - Management expressed confidence in sustaining operational momentum and improving cash flow in Q4 2025 [6][8] Recent Developments - On September 17, 2025, Vext received regulatory approval to transfer ownership of the Herbal Wellness Center dispensary in Portsmouth, Ohio, completing the transfer on October 1, 2025 [9]

Core Insights - Vext Science, Inc. reported a revenue of $12.7 million for Q3 2025, representing a 41% increase year-over-year, driven by expanded retail operations in Ohio and resilient performance in Arizona [4][5] - Year-to-date operating cash flow reached $8.5 million, a significant improvement compared to $(0.7) million in the same period last year [5] - The company is on track to expand its retail footprint in Ohio, aiming to reach the state dispensary license cap of eight by 2026 [5][18] Financial Performance - Q3 2025 revenue was $12,670,000, compared to $13,407,000 in Q2 2025 and $8,987,000 in Q3 2024 [3] - EBITDA for Q3 2025 was $2,315,000, down from $5,263,000 in Q2 2025 but up from $1,925,000 in Q3 2024 [3][10] - Adjusted EBITDA for Q3 2025 was $2,112,000, with an adjusted EBITDA margin of 16.7%, compared to 30% in Q2 2025 and 32% in Q3 2024 [3][10] Operational Highlights - The company has strengthened its retail presence in Ohio, consolidating operations to five locations and planning for three additional dispensaries [5][18] - Vext's operational discipline has allowed it to outperform state averages in Arizona, maintaining steady performance despite broader market declines [4] - The company expects continued operational momentum and improved cash flow in Q4 2025 as it addresses inventory built in Q3 [4]

Core Points - Vext Science, Inc. plans to announce its financial results for Q3 2025 on November 20, 2025, before market open [1] - A conference call and webcast will be held on the same day at 08:00 a.m. ET to discuss the financial results [2] Company Overview - Vext Science, Inc. is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, focusing on cultivation, manufacturing, and retail [4] - The company owns state-of-the-art cultivation and manufacturing facilities, as well as dispensaries in its key markets [4] - Vext manufactures Vapen™, a leading brand of THC concentrates, edibles, and distillate cartridges in Arizona, utilizing high-quality in-house flower [4] - The leadership team has a proven track record in building and operating profitable multi-state operations, with a focus on growth in Arizona and Ohio [4]

Core Insights - Vext Science, Inc. has received regulatory approval to transfer ownership of the Herbal Wellness Center dispensary in Portsmouth, Ohio, which will become its fifth fully consolidated dispensary in the state by October 1, 2025 [1][2][14] - The company is actively working on three additional dispensary locations in Ohio, aiming to reach the maximum state cap of eight dispensaries by early 2026 [3][13] Company Expansion Strategy - The acquisition of the Portsmouth dispensary is part of Vext's disciplined growth strategy in Ohio, enhancing its retail footprint and supporting margin expansion and cash flow generation [2][3] - Vext's commitment to compliance, community engagement, and high-quality product delivery is central to its operational success in the growing Ohio cannabis market [2] Operational Status - The Portsmouth Dispensary features a drive-thru for customer convenience and was granted a provisional license under the Ohio Division of Cannabis Control [2] - Vext's existing facilities in Ohio include fully operational cultivation and manufacturing facilities, as well as multiple dispensaries serving both medical and adult-use consumers [4][7] Future Developments - Vext plans to open additional dispensaries, with the sixth dispensary in Fairfield, Ohio, expected to be operational by Q4 2025 [6] - The company has identified target locations for two more dispensaries, pending the issuance of provisional permits [6][13]

Core Insights - Vext Science, Inc. reported record financial results for Q2 2025, with revenue reaching $13.4 million, a 59% increase year-over-year, and a strong cash flow margin of 31% [4][7][3] Financial Performance - Revenue for Q2 2025 was $13,407,000, compared to $11,561,000 in Q1 2025 and $8,427,000 in Q2 2024 [3] - Adjusted EBITDA for Q2 2025 was $4,077,000, up from $3,357,000 in Q1 2025 and $1,084,000 in Q2 2024, reflecting a significant year-over-year increase [3][13] - Operating cash flow for Q2 2025 was $4,175,000, compared to $(592,000) in Q2 2024 and $3,082,000 in Q1 2025, indicating improved operational efficiency [3][11] Market Dynamics - The growth in revenue and adjusted EBITDA was driven by strong performance in Ohio, where retail sales increased by 86% sequentially [4][7] - Vext is on track to reach the state dispensary license cap of eight by early 2026, enhancing its market presence in Ohio [7][22] Operational Highlights - The company maintained profitability in Arizona despite market contraction by focusing on sell-through on its own retail shelves [4] - Vext's disciplined operations and scalable footprint contributed to its strong cash flow generation and overall financial health [4][7] Recent Developments - Vext completed the acquisition of two cannabis dispensaries in Ohio, which contributed to the revenue growth in Q2 2025 [12] - The company has plans to open additional dispensaries, including a new location in Fairfield, Ohio, expected to begin operations in Q4 2025 [12][22]

Core Viewpoint - Vext Science, Inc. is set to announce its financial results for Q2 2025 on August 20, 2025, before market open, and will host a conference call to discuss these results [1][2]. Company Overview - Vext Science, Inc. operates as a U.S.-based cannabis company with vertical operations in Arizona and Ohio, focusing on cultivation, manufacturing, and retail [4]. - The company owns state-of-the-art cultivation and manufacturing facilities, as well as dispensaries in its key markets [4]. - Vext manufactures Vapen™, a leading brand of THC concentrates, edibles, and distillate cartridges in Arizona, utilizing high-quality in-house flower [4]. - The leadership team has a proven track record in building and operating profitable multi-state operations, with a focus on growth in Arizona and Ohio [4]. Financial Communication - The financial results for Q2 2025 will be released before the market opens on August 20, 2025, followed by a conference call at 8:00 a.m. ET [1][2]. - Participants can join the call via specific dial-in numbers, and a replay will be available afterward on Vext's investor website [3].